Next, we evaluated the predictive value of an increased percentage of CD57+ CD8 T cells at the first or second time point in patients who would only subsequently develop hepatopathy up to July 2023, as the prevalence of this complication increased from 10 (7.6%) at the first to 18 (14%) at the second timepoint and up to 24 (18%) in July 2023. This evidence concerns the gene CD8A and Decreased liver function.